Innovative combination clinical trial results revealed at ASCO

MD安德森researchers will present临床试验结果有前途的联合疗法适用于多种在临床肿瘤学（ASCO）年会上的2019美国社会，这周五开始在芝加哥癌症的。

The ASCO session brings together more than 32,000 oncology professionals from around the world to share the latest cancer treatment and oncology research results. Among highlighted findings from hundreds of presentations byMD安德森临床医生和科学家是：

• Overall survival results for premenopausal patients who receive atargeted therapywith hormonal therapy for hormone-receptor-positive乳腺癌。
• 患者主要病理反应谁收到immunotherapycombination before undergoing surgery for their locally advanced non-small celllung cancer。
• 高响应率弥漫性大B细胞淋巴瘤谁才去接受靶向治疗联合用药chemotherapy。

Details of the breast cancer treatment findings, a massive study led byDebu Tripathy, M.D.，主席乳腺肿瘤内科，将提前释放周六上午在会议上，将在MD安德森的覆盖newsroom。

在III期试验，被称为MONALEESA-7（ASCO摘要LBA1008), compared adding the targeted therapy ribociclib to hormone therapy vs. hormone therapy and a placebo. Ribociclib inhibits cyclin-dependent kinases 4/6 (CDK4/6), proteins vital to cell cycle function.

Ribociclib是在2018年美国食品和药物管理局对治疗绝经前晚期HR +乳腺癌与激素疗法的基础上，无进展生存期数据从MONALEESA-7的批准。

Pre-surgical immunotherapy for lung cancer

新辅助治疗免疫抑制剂检查站nivolumab与易普利姆玛导致患者超过30％的主要病理反应的早期阶段，可切除肺癌的第二阶段NEOSTAR trial（摘要8504) conducted at MD Anderson.

主要的病理学响应被定义为剩余在手术活肿瘤的小于10％。

试验结果表明，免疫治疗结合案情的进一步分析说，主要研究者Tina Cascone, M.D., Ph.D., assistant professor of胸/头颈部肿瘤内科。

大约一半的人与谁是手术治疗单纯最终有复发可能治愈疾病早期阶段。

该试验招募44名患者，随机分为nivolumab（抗PD-1）单独或nivolumab加易普利姆玛（抗CTLA-4）。六例（38％）接受联合治疗相比于接收nivolumab两名患者（10％）达到完全应答。

研究人员188bet体育网址分析来自生物样本数据时和治疗指导未来的研究和临床试验前后拍摄。

三靶向治疗大B细胞淋巴瘤

A combination targeted therapy – rituximab, lenalidomide and ibrutinib (RLI) – achieved an 84.6% overall response rate and 38.5% complete response rate when given before chemotherapy for newly diagnosed patients with non-germinal center diffuse large b-cell lymphoma (DLBCL) in a Phase II clinical trial (ASCO摘要7508).

Study leaderJason Westin, M.D., assistant professor of淋巴瘤& Myeloma.称前结果显著。”All patients have gone on to receive standard chemotherapy in combination with these targeted treatments per the protocol, and, so far, we’ve had a 100 percent response rate,” Westin says.

Large-cell lymphomas are diagnosed in approximately 30,000 individuals each year in the U.S. Non-germinal center cases account for an estimated 30-40% of those cases and does not respond as well to standard-of-care chemotherapy.